Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Zhendong Chen"'
Autor:
Jianfeng Zhou, Dong Ma, Hongbing Wang, Qiang Zhang, Changping Wu, Ying Yuan, Lei Yang, Ning Wang, Nong Xu, Zhuang Yu, Rui-Hua Xu, Wei Li, Yongqian Shu, Shubin Wang, Ying Cheng, Jin Li, Weijian Guo, Peiguo Cao, Zhendong Chen, Xiaojun Guo, Sanyuan Sun, Shukui Qin, Weiguo Su, Bin Zhang, Yuxian Bai, Jianming Xu, Hongming Pan, Haihui Chen, Donghui Chen, Tianshu Liu, Jiejun Wang, Yanhong Deng, Lin Shen, Haijun Zhong
Publikováno v:
OncoTargets and Therapy, Vol Volume 14, Pp 4439-4450 (2021)
OncoTargets and therapy
OncoTargets and therapy
Shukui Qin,1 Rui-Hua Xu,2 Lin Shen,3 Jianming Xu,4 Yuxian Bai,5 Lei Yang,6 Yanhong Deng,7 Zhen-dong Chen,8 Haijun Zhong,9 Hongming Pan,10 Weijian Guo,11 Yongqian Shu,12 Ying Yuan,13 Jianfeng Zhou,14 Nong Xu,15 Tianshu Liu,16 Dong Ma,17 Changping Wu,1
Autor:
Zhendong Chen, Hongbing Wang, Shukui Qin, Peiguo Cao, Weiguo Su, Sanyuan Sun, Haihui Chen, Jian Li, Jianfeng Zhou, Haijun Zhong, Yanhong Deng, Rubing Han, Lei Yang, Shubin Wang, Weijian Guo, Donghui Chen, Dong Ma, Xiaojun Guo, Rui-Hua Xu, Wei Li, Zhuang Yu, Ying Cheng, Tianshu Liu, Jin Li, Yongqian Shu, Bin Zhang, Jiejun Wang, Hongming Pan, Jianming Xu, Yuxian Bai, Ning Wang, Nong Xu, Changping Wu, Ying Yuan
Publikováno v:
Future Oncology. 17:1339-1350
Background: FRESCO study demonstrated efficacy and safety of fruquintinib in metastatic colorectal cancer patients. Impact of prior targeted therapy (PTT) on efficacy and safety of fruquintinib was evaluated. Materials & methods: In this subgroup ana
Autor:
Weijian Guo, Rubing Han, Zhendong Chen, Nong Xu, Lei Yang, Shubin Wang, Haijun Zhong, Donghui Chen, Rui-Hua Xu, Wei Li, Ning Wang, Ying Yuan, Shukui Qin, Songhua Fan, Xiaojun Guo, Peiguo Cao, Yongqian Shu, Zhuang Yu, Jianfeng Zhou, Bin Zhang, Hongbing Wang, Dong Ma, Lin Shen, Hongming Pan, Ying Cheng, Sanyuan Sun, Changping Wu, Jianming Xu, Yuxian Bai, Haihui Chen, Yanhong Deng, Jin Li, Tianshu Liu
Publikováno v:
Advances in Therapy. 37:4585-4598
In FRESCO (Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients) trial, fruquintinib demonstrated a statistically significant and clinically meaningful overall survival benefit in Chinese patients with metastatic colorectal cancer (
Autor:
Jianming Ying, Hongming Pan, Lunxu Liu, Zhiqiang Meng, Zhendong Chen, F. Bi, Helong Zhang, Ping Yang, Shanzhi Gu, Zishu Wang, Xi Chen, A. Xu, Yiping Lu, Shukui Qin, Yuxian Bai
Publikováno v:
Annals of Oncology. 32:S820
Publikováno v:
Tumor Biology. 35:6011-6020
We performed a meta-analysis of cohort studies to determine whether promoter methylation of the death-associated protein kinase (DAPK) gene contributes to the pathogenesis of nonsmall cell lung cancer (NSCLC). A range of electronic databases were sea
Autor:
Jin Li, Haidong Chi, Jack Peng, Weijian Guo, Ye Hua, Lei Yang, Lin Shen, Ning Wang, Yongqian Shu, Zhendong Chen, Weiguo Su, Hongming Pan, Shukui Qin, Ying Yuan, Yuxian Bai, Xin Wang, Yanhong Deng, Haijun Zhong, Jianming Xu, Rui-Hua Xu
Publikováno v:
Journal of Clinical Oncology. 36:3537-3537
3537Background: Patients with mCRC are typically offered chemotherapy and might also receive target therapy-drugs targeting VEGF or EGFR. In phase 3 FRESCO trial, fruquintinib demonstrated a statis...
Publikováno v:
Tumor Biology. 36:7303-7303
We performed a meta-analysis of cohort studies to determine whether promoter methylation of the death-associated protein kinase (DAPK) gene contributes to the pathogenesis of nonsmall cell lung cancer (NSCLC). A range of electronic databases were sea